• FLG mutations cause atopic dermatitis, previously found to be associated with ischemic stroke.
Introduction
Ischemic stroke is one of the leading causes of death and disability worldwide and identifying risk factors is of crucial importance for preventing the disease. Heritability studies have shown a considerable genetic component to ischemic stroke risk; however, much is still unknown as to which genes are responsible [1] .
Observational studies have shown conflicting results, with some studies reporting an association between atopic dermatitis and increased risk of ischemic stroke [2] [3] [4] , and it has been hypothesized that FLG mutations might be the explanation. However, a previous study of 13 373 individuals found only a borderline significant association between FLG mutations and risk of stroke, with a hazard ratio of 1.27 (95% confidence interval [CI] , 0.97-1.65) [5] , which could have been caused by lack of power as result of low sample size. FLG encodes filaggrin, which is an epidermal protein expressed in the outer layers of the epidermis. Mutations in FLG are common among individuals of northern European ancestry, with approximately 10% of the population being heterozygous for a loss-offunction mutation. FLG mutations are well-known risk factors for atopic dermatitis, and in individuals with atopic dermatitis FLG mutations are associated with asthmatic bronchitis and contact allergies [6] [7] [8] .
We genotyped 97 174 individuals from the Copenhagen General Population Study (N = 86 341), the Copenhagen City Heart Study (N = 10 390) and the Copenhagen Carotid Stroke Study (N = 443) for the two most common loss-of-function FLG mutations, FLG R501X and FLG 2282del4, and tested for association with risk of ischemic stroke. We also tested whether the FLG mutations were associated with conventional cardiovascular risk factors that might explain the association with ischemic stroke. Information on self-reported eczema was available in the Copenhagen General Population Study, and associations between FLG mutations and self-reported eczema, and between self-reported eczema and risk of ischemic stroke, were also examined.
Methods
The studies were approved by Herlev and Gentofte Hospital and Danish ethical committees (H-KF-01-144/ 01; KF-100.2039/91; KF-01-144/01; KF-01-062/94; KF-01-375/94; KA-99039), and were conducted according to the Declaration of Helsinki with informed written consent from individuals. All individuals were white and of Danish descent and none appeared in more than one study.
The Copenhagen General Population Study
This is a prospective study of the general population initiated in 2003 with ongoing enrollment [9] . Individuals were randomly selected from the national Danish Civil Registration System to reflect the adult population aged 20-100+ years. Median age at baseline was 58 years (interquartile range, 48-67 years). Data collection included a questionnaire, physical examination and blood sampling for biochemical analyses and DNA extraction. Information on self-reported eczema was available from the questionnaires, with individuals answering yes or no to the question: Does any type of food, medicine, grass, flowers, animal-hairs, or anything else give you eczema? A total of 86 341 individuals with information on both FLG genotypes and ischemic stroke were included in analyses using genotypes; 93 612 individuals with information on self-reported eczema and genotypes were included in analyses of association between FLG and eczema; and 84 601 individuals with information on selfreported eczema and ischemic stroke were included in analyses of association between eczema and ischemic stroke.
The Copenhagen City Heart Study
This is a prospective study of the general population initiated in 1976-1978 with follow-up examinations in 1981-1983, 1991-1994 and 2001-2003 [10,11] . Individuals were recruited and examined exactly as in the Copenhagen General Population Study. Median age at baseline was 58 years (interquartile range: 43-69 years). Blood samples for biochemical measurements and DNA extraction were drawn at the 1991-1994 and 2001-2003 examinations. A total of 10 390 individuals with information on FLG genotypes and ischemic stroke were included.
The Copenhagen Carotid Stroke Study
This case-control study comprises patients referred for ultrasonography of the carotid artery at Rigshospitalet, Copenhagen University Hospital, during the period 1994-2011 [12] (with controls from the prospective studies); 443 patients with > 50% occlusion of the internal carotid artery at examination, with information on FLG genotype and with a diagnosis of ischemic stroke, were included. Median age at baseline was 64 years (interquartile range, 58-70 years).
Ischemic stroke
Diagnoses of ischemic stroke (ICD8: 431-438; ICD10: I60-I69 + G45) were collected from 1976 until July 2013 by reviewing all hospital admissions and diagnoses entered in the national Danish Patient Registry and all causes of death entered in the national Danish Causes of Death Registry. The Danish registers contain information on all individuals and follow-up is therefore without losses. For individuals with registered cerebrovascular disease, hospital records were requested and the diagnosis of ischemic stroke validated by two independent medical doctors blinded to the test results and genotypes [13, 14] . The diagnostic criterion for ischemic stroke was focal neurological symptoms > 24 h. Hemorrhagic stroke and subarachnoidal hemorrhage were excluded from the ischemic stroke group. To distinguish among infarction, intracerebral hemorrhages and subarachnoidal hemorrhages, either computed tomography (CT) or magnetic resonance imaging (MRI) scan, autopsy, spinal fluid examination or surgical description was necessary. If a scan did not visualize an infarction or hemorrhage, but the individual had symptoms that met the criteria of the stroke definition, then the event was diagnosed as ischemic stroke. The diagnosis of ischemic stroke was not applied in cases where a scan revealed signs of prior cerebrovascular disease, but without history of any symptoms.
Laboratory analyses
Standard hospital assays measured non-fasting triglycerides, high-density lipoprotein cholesterol, glucose, highsensitivity C-reactive protein (hsCRP), activated partial thromboplastin time (APTT), coagulation factors II-VII-X and vitamin D. Low-density lipoprotein cholesterol was calculated using the Friedewald equation when plasma triglycerides were ≤ 4 mM, and otherwise measured directly.
Genotypes
Genotyping of FLG 2282del4 was by TaqMan (Applied Biosystems, Foster City, CA, USA), with genotypes verified by sequencing of a subset of individuals. FLG R501X was genotyped by LGC Genomics (Hoddesdon, UK) using a competitive allele-specific PCR system (KASPar). Call rates were > 99%. Genotype frequencies did not differ from Hardy-Weinberg equilibrium.
Other covariates
Smoking was never, current and former. Cumulative tobacco consumption was in pack-years (one packyear % 20 cigarettes day À1 per year). Diabetes was self-reported disease, use of anti-diabetic medication, nonfasting glucose > 11 mM and/or hospitalization because of diabetes before baseline (ICD8: 249, 250; ICD10: E10, E11, E13, E14). Lipid-lowering therapy was self-reported. Body mass index was measured weight (kg) divided by measured height squared (m 2 ). Systolic and diastolic blood pressures were measured at study inclusion. Alcohol consumption was self-reported as grams of alcohol per week (one drink~12 grams of alcohol). Physical activity in leisure time was divided into (i) mainly passive (light activity < 2 h week À1 ), (ii) lightly active (light activity Detailed descriptions of covariates in the Copenhagen City Heart Study have been published previously [10] , and in the Copenhagen General Population Study covariates were ascertained in a similar way. For the Copenhagen Carotid Stroke Study only age and sex were used as covariates.
Statistical analysis
Data were analyzed using Stata (13.1). FLG 2282del4 and FLG R501X were examined separately and combined to maximize statistical power. A FLG 2282del4 and FLG R501X mutation allele score was constructed by adding the number of FLG alleles in each individual (0 = noncarrier, 1 = heterozygote, 2 = homozygote of each of the mutations). Also, individuals were grouped by FLG mutation (no/yes).
Association between FLG mutations and risk of ischemic stroke was examined in 97 179 individuals, with 3597 cases of ischemic stroke, from the Copenhagen General Population Study, the Copenhagen City Heart Study and the Copenhagen Carotid Stroke Study combined using logistic regression with adjustment for age and sex. In a sensitivity analysis, the association between FLG mutations and risk of ischemic stroke was additionally adjusted for current smoking, former smoking, cumulative tobacco consumption, body mass index and physical activity in leisure time and at work. This analysis was restricted to the Copenhagen General Population Study and the Copenhagen City Heart Study because of availability of covariates.
Association between FLG mutations and risk of ischemic stroke stratified by age < 50 or ≥ 50 years was examined in the Copenhagen General Population Study and the Copenhagen City Heart Study combined by logistic regression and adjusted for age and sex. Association between FLG mutations and risk of ischemic stroke stratified by sex was examined in the Copenhagen General Population Study, the Copenhagen City Heart Study and the Copenhagen Carotid Stroke Study combined by logistic regression and adjusted for age. Association between FLG mutations and risk of ischemic stroke stratified by smoking status was examined by logistic regression adjusted for age and sex in the Copenhagen General Population Study and the Copenhagen City Heart study combined, and the association between FLG mutations and risk of ischemic stroke stratified by self-reported eczema was examined in the Copenhagen General Population Study. Interaction tests were by likelihood ratio tests.
Absolute 10-year risk of ischemic stroke was examined in the Copenhagen General Population Study and the Copenhagen City Heart Study prospectively using Poisson regression with covariates FLG mutation (no/yes), sex, age < 50 or ≥ 50 years, current smoking and hypertension. Population attributable risk in % was estimated by the equation f (RR-1)/(1 + (f (RR À 1)) 9 100%, where f was the incidence of FLG mutations and RR was the incidence rate ratio estimated by Poisson regression adjusted for age and sex.
Association between FLG mutations and self-reported eczema was examined in 93 612 individuals, with 9175 cases of self-reported eczema from the Copenhagen General Population Study, using logistic regression and adjusted for age and sex.
Association between self-reported eczema and risk of ischemic stroke was examined in the Copenhagen General Population Study by Cox proportional hazards regression models with age as the time scale and with use of left truncation and delayed entry; individuals diagnosed with ischemic stroke before study entry were excluded, those dying during follow-up were censored at their death and those who emigrated were censored at their emigration date. Median follow-up time was 5 years (range, 0-9 years). Hazard ratios were adjusted for age and sex or multifactorially adjusted for age, sex, current and former smoking, cumulative tobacco consumption, lipid-lowering therapy, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, diabetes, alcohol consumption, systolic and diastolic blood pressure, body mass index, physical activity in leisure time and at work, and atrial fibrillation. Table 1 shows characteristics of individuals from the Copenhagen General Population Study by FLG loss-offunction mutation status. After Bonferroni correction, there were no differences in conventional cardiovascular risk factors or coagulation factors, except for slightly more pack-years of smoking for individuals with FLG mutations compared with non-carriers (P-value = 0.02). Also, FLG mutation carriers had a higher level of vitamin D than non-carriers (P-value = 3 9 10
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Association between FLG loss-of-function mutations and ischemic stroke
For the FLG 2282del4 and FLG R501X mutation allele score, carriers of one allele had an odds ratio for ischemic stroke of 1.15 (95% CI, 1.02-1.30) and carriers of two alleles an odds ratio of 1.25 (0.63-2.48; P-fortrend = 0.02), compared with non-carriers (Fig. 1) . When combined into no or yes to any FLG mutation, mutation carriers had an odds ratio for ischemic stroke of 1.15 (1.02-1.30; P-value = 0.02); that is, FLG mutation carriers had a 15% increased risk of ischemic stroke compared with non-carriers.
Association between FLG loss-of-function mutations and ischemic stroke: additional adjustment
In a sensitivity analysis, the association between FLG lossof-function mutations and risk of ischemic stroke was multifactorially adjusted for age, sex, current and former smoking, cumulative tobacco consumption, body mass index, and physical activity in leisure time and at work ( Figure S1 ). This was restricted to the Copenhagen General Population Study and the Copenhagen City Heart Study because of availability of covariates. Multifactorially adjusted odds ratios were similar to age and sex-adjusted odds ratios (compare Figure S1 with Fig. 1) , with a multifactorially adjusted odds ratio for ischemic stroke for any FLG loss-of-function mutation of 1.16 (95% CI, 1.02-1.32; P-value = 0.03) compared with non-carriers.
Association between FLG loss-of-function mutations and ischemic stroke: the Copenhagen Carotid Stroke Study
In a sensitivity analysis, the association between FLG loss-of-function mutations and risk of ischemic stroke was examined in a case-control design with cases from the Copenhagen Carotid Stroke Study matched by age and sex with controls without ischemic stroke from the Copenhagen General Population Study. Mutation carriers had an odds ratio for ischemic stroke of 1.13 (0.70-1.83).
Association between FLG loss-of-function mutations and ischemic stroke stratified by age and sex
The risk of ischemic stroke for FLG mutation carriers was increased among individuals < 50 years, with an odds ratio of 1.72 (95% CI, 1.11-2.67; P-value = 0.01), compared with non-carriers. For individuals ≥ 50 years the odds ratio for ischemic stroke was 1.13 (0.99-1.29; P-value = 0.07) for FLG mutation carriers compared with non-carriers. Even though the odds ratio for ischemic stroke was higher for individuals < 50 years than for individuals ≥ 50 years, there was no statistical indication of interaction with age (P-for-interaction = 0.13) (Fig. 2) .When stratified by sex there was no pronounced difference in risk of ischemic stroke, with P-for-interaction = 0.50.
Association between FLG loss-of-function mutations and ischemic stroke stratified by smoking
When stratified by smoking status, association between FLG mutations and increased risk of ischemic stroke was seen in current and former smokers, with an odds ratio of 1.25 (95% CI: 1.08-1.44, P-value = 0.003) compared with non-carriers; however, there was no association in individuals who had never smoked (Fig. 3 ). Despite this difference between ever and never smokers, there was no statistical indication of an effect of interaction between FLG mutation no/yes and never/ever smoking on risk of ischemic stroke, with P-forinteraction = 0.07.
Association between FLG loss-of-function mutations and ischemic stroke stratified by self-reported eczema
When stratified by self-reported eczema there was no pronounced difference in risk of ischemic stroke (Fig. 4) , and no statistical indication of effect of interaction between FLG mutation no/yes and self-reported eczema no/yes on risk of ischemic stroke, with P-for-interaction = 0.63.
Association between FLG loss-of-function mutations and ischemic stroke: absolute risk
In the Copenhagen General Population Study and the Copenhagen City Heart Study combined, incidence rates for ischemic stroke were 3.3 cases per 1000 person-years (95% CI, 3.2-3.5) for non-carriers of FLG loss-of-function mutations, and 3.8 cases per 1000 person-years (3.3-4.4) for FLG mutation carriers. The population attributable risk was 1% for FLG mutations; that is, 1% of the risk of ischemic stroke could be prevented if FLG mutations were not present in the Danish population. When stratifying for age, sex, smoking and hypertension the absolute 10-year risk of ischemic stroke was higher among FLG mutation carriers compared with noncarriers in all groups (Fig. 5) risk between FLG mutation carriers and non-carriers was 1.5%, and was seen in individuals with the highest overall risk; that is, in men aged ≥ 50 years with hypertension and current smoking, where the 10-year risk for ischemic stroke was 14.7% for FLG mutation carriers and 13.2% for FLG non-carriers.
Association between FLG loss-of-function mutations and self-reported eczema FLG mutation carriers had increased risk of self-reported eczema, with an odds ratio of 1.42 (1.32-1.52; P-value < 0.001) for mutation carriers compared with non-carriers (Fig. 6 ).
Association between self-reported eczema and ischemic stroke
Individuals from the Copenhagen General Population Study with self-reported eczema had increased risk of ischemic stroke, with an age and sex-adjusted hazard ratio of 1.24 (95% CI, 1.01-1.52; P-value = 0.04) compared with individuals without self-reported eczema (Fig. 7) ; however, the association was attenuated and not statistically significant after adjustment for conventional cardiovascular risk factors, with a hazard ratio of 1.19 (0.96-1.48; P-value = 0.11) compared with individuals without self-reported eczema.
Discussion
In this study of 97 174 individuals from the general population of Denmark, we found an association between the two most common FLG loss-of-function mutations, R501X and 2282del4, and a 15-25% increased risk of ischemic stroke. This study is to our knowledge the largest study of FLG mutations in the general population and the first to find an association with ischemic stroke. The explanation for the association between FLG mutations and ischemic stroke is at present unclear. Some previous epidemiological studies have found associations between atopic dermatitis or eczema and cardiovascular risk factors; however, results have been conflicting. A meta-analysis found an association between atopic dermatitis and overweight and obesity, although only in USA and Asian populations and not in European populations [15] . Also, using information from the National Health Interview Survey, Silverberg et al. found higher odds of smoking, higher alcohol intake, hypertension, higher body mass index, pre-diabetes and lower odds of vigorous physical activity for individuals with eczema compared with individuals without eczema [16] . Atopic dermatitis has been associated with less physical activity in a study from the USA [17] , but a Swedish study found no association between atopic dermatitis and physical activity [18] . In the present study, we found no association between FLG mutations and common risk factors for ischemic stroke such as lipoprotein levels, blood pressure, diabetes, atrial fibrillation or lifestyle habits such as alcohol intake, physical activity and current or former smoking; however, we found that carriers of FLG mutations had smoked slightly more pack-years than non-carriers. Also, when stratifying for smoking status, the increased risk of ischemic stroke for FLG mutation carriers was seen in current and former smokers and there was no association between FLG mutations and ischemic stroke in individuals who had never smoked; however, there was no statistical sign of an effect of interaction between FLG mutations and smoking status on risk of ischemic stroke. A possible explanation for the association between FLG mutations and ischemic stroke risk could also be the previously observed associations between atopic dermatitis and other autoimmune diseases such as diabetes mellitus type 1 [19, 20] , rheumatoid arthritis [20] , inflammatory bowel disease [20] , lupus erythematosus [21, 22] and coeliac disease [23] ; however, results have been conflicting [24] and causality has not been determined. Also, a recent Danish register study [25] found a higher occurrence of several autoimmune diseases in adults with atopic dermatitis, and especially in individuals with a history of smoking.
Another possible explanation for the association between FLG mutations and higher risk of ischemic stroke could be a general state of low-grade inflammation or changes in the coagulation system in individuals with atopic dermatitis [26] [27] [28] ; however, we did not find an association between FLG mutation status and plasma concentrations of CRP, APTT or coagulation factors II-VII-X.
We found an association between FLG mutations and higher vitamin D levels in accordance with previous findings [29] . Vitamin D levels are associated with ischemic stroke risk in observational studies [30] ; however, low vitamin D levels were associated with high risk of ischemic stroke, which is the opposite direction to the high risk of ischemic stroke we observed in mutation carriers. Also, whether low vitamin D is causal for development of ischemic stroke or just a marker of risk is unknown. For eczema patients, there has been conflicting evidence of the association with vitamin D, with some studies finding eczema patients to have lower levels of vitamin D in a dose-dependent manner [31] . In line with our findings for the FLG mutations and higher risk of ischemic stroke, we also found self-reported eczema to be associated with higher risk of ischemic stroke; however, the association attenuated and was no longer statistically significant after multifactorial adjustment, as also seen in some previous studies of the association between atopic dermatitis and stroke. Previous register-based and observational cohort studies have had conflicting results regarding the association between atopic dermatitis and stroke. A nationwide register study from Taiwan [2] found an association between atopic dermatitis and ischemic stroke, with a 33% (95% CI, 12-59%) higher risk in individuals with atopic dermatitis compared with controls. Another nationwide register study from Denmark [4] found an association between a register-based diagnosis of severe atopic dermatitis and higher risk of ischemic stroke; however, the association was not statistically significant after multifactorial adjustment for socioeconomic status, a register-based proxy for smoking, co-morbidities and medication use. The same study found that mild atopic dermatitis was associated with decreased risk of ischemic stroke compared with individuals without atopic dermatitis. In a study by Silverberg [3] using information on > 65 000 individuals from the National Health and Nutrition Examination Study and the National Health Interview Survey, an association between eczema and higher risk of stroke was observed, with the association persisting after adjustment for cardiovascular risk factors in the National Health Interview Survey but not in the National Health and Nutrition Examination Study. Also, Drucker et al. [32] found an association between atopic dermatitis and non-fatal stroke in 78 702 participants from the Nurses Health Study; however, the association was not statistically significant after adjustment for cardiovascular risk factors. In contrast to the findings in some of these previous observational studies, in the present study the association between FLG mutations and increased risk of ischemic stroke was similar when adjusted for cardiovascular risk factors compared with age and sex adjustment only; however, residual confounding may have affected our estimates (e.g. factors associated with a sedentary lifestyle, which cannot be adjusted for, could have affected the results). The absolute risk of ischemic stroke was increased for FLG mutation carriers compared with non-carriers, and although the difference in absolute 10-year risk was not as pronounced as for the well-known risk factors smoking and hypertension, the odds ratio in the cross-sectional design was of a similar magnitude to the known genetic risk factors for ischemic stroke identified by candidategene analyses and genome-wide association studies [1] .
The odds ratio for ischemic stroke for FLG mutation carriers compared with non-carriers was higher among individuals < 50 years than for individuals ≥ 50 years of age. It can be argued that this is not surprising as younger individuals have a low incidence of the disease and lower incidence of other risk factors for ischemic stroke, such as hypertension, hyperlipidemia and atrial fibrillation, whereas genetic mutations on the other hand are present for life.
Why the association between FLG mutations and risk of ischemic stroke was similar after adjustment for common cardiovascular risk factors, while the association between self-reported eczema and ischemic stroke was no longer statistically significant after multifactorial adjustment, is not known. A likely explanation could be that individuals with self-reported eczema are a heterogeneous group with different underlying causes of eczema. There might be subgroups of individuals with underlying causes of eczema that are more associated with cardiovascular risk factors and ischemic stroke than others. Also, although self-reported eczema may not be present for life, FLG mutations are, and therefore estimates for the mutations could be more stable.
A major strength of our study is the large sample size of individuals from the general population with valid information on covariates, morbidity and mortality because of the completeness of the Danish registers. The Copenhagen General Population Study and the Copenhagen City Heart Study are both large prospective studies of the general population, and the Copenhagen Carotid Stroke Study was included to maximize statistical power, because even though the study adds only a small number of individuals, they are all cases of ischemic stroke.
A limitation of the study is lack of information from a dermatologic examination of individuals. Self-reported eczema is not as accurate as a diagnosis of atopic dermatitis by a dermatologist; however, as inaccurate diagnoses of eczema are likely to be non-differential in relation to FLG genotypes and thus bias the results towards the null hypothesis, and as we did find an association between FLG mutations and self-reported eczema, the corresponding true associations might be even stronger in individuals with a specialist verified diagnosis of atopic dermatitis. However, because of lack of accurate diagnoses of atopic dermatitis, we were not able to examine whether the risk of ischemic stroke was increased in Fig. 7 . Association between self-reported eczema and ischemic stroke. Association between self-reported eczema and risk of ischemic stroke was by Cox proportional hazards regression models in the Copenhagen General Population Study. Hazard ratios were adjusted for age and sex or multifactorially adjusted for age, sex, current and former smoking, cumulative tobacco consumption in pack-years, lipid-lowering therapy, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, diabetes, alcohol consumption, systolic and diastolic blood pressure, body mass index, physical activity in leisure time and at work, and atrial fibrillation. CI, confidence interval; HR, hazard ratio; N, number.
individuals with both a diagnosis of atopic dermatitis and FLG mutations. Also, even though we found FLG mutations were associated with an odds ratio for ischemic stroke of 1.15 (95% CI, 1.02-1.30), the odds ratio for self-reported eczema was nominally higher at 1.42 (1.32-1.52). Although individuals in this study were genotyped for the two most common FLG loss-of-function mutations, FLG R501X and FLG 2282del4, other mutations in the FLG gene are likely to be present within the general population, and associations between other FLG mutations and ischemic stroke risk are still unknown.
In conclusion, in this study of 97 174 individuals from the Danish general population, we found an association between FLG loss-of-function mutations and increased risk of ischemic stroke, which has not been reported previously; however, there is a possibility of residual confounding affecting the results.
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